Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of miR-4707-3p expression on differentiation of primary human neural progenitor cells

ABSTRACT: To test the effects of miR-4707-3p expression on gene expression and differentiation of primary human neural progenitor cells (phNPCs), we produced two doxycycline inducible stable cell lines using lentiviral transduction. Lines expressed either mir-4707 and GFP or only GFP using the pTRIPZ expression vector. Stable lines were grown in differentiation media with doxycycline for one or two weeks before RNA was extracted and assayed on a Clariom S Pico Microarray Assay.

ORGANISM(S): Homo sapiens

PROVIDER: GSE224188 | GEO | 2023/02/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq following shRNA-mediated knock-down of ETV6-RUNX1 in the B-ALL cell line Reh

Project description:Stable derivatives of the Reh cell line carrying inducible shRNAs were generated by transducing with lentivirus harbouring the pTRIPZ vector and enabling doxycycline-inducible expression of shRNAs together with an RFP reporter. Two independent lines carrying different shRNAs targeting ETV6 or a vector control were generated. Cells were treated for 0 or 7 days with doxycycline, and harvested for bulk RNA-seq.

2022-04-10 | E-MTAB-10308 | biostudies-arrayexpress

Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs [SPR1108]

Project description:Acquired resistance to cancer drug therapies almost always occurs in advanced-stage patients even following a significant response to treatment. In addition to mutational mechanisms, various non-mutational resistance mechanisms have now been recognized. We previously described a chromatin-mediated subpopulation of reversibly drug-tolerant persisters (DTPs) that is dynamically maintained within a wide variety of tumor cell populations. Here, we explored a potential role for microRNAs in such transient drug tolerance. Functional screening of 879 human microRNAs revealed miR-371-3p as a potent suppressor of drug tolerance. PRDX6 (peroxiredoxin 6) was identified as a key target of miR-371-3p in establishing drug tolerance by regulating PLA2/PKCÎ± activity and reactive oxygen species. PRDX6 expression is associated with poor prognosis in cancers of multiple tissue origins. These findings implicate miR-371-3p as a suppressor of PRDX6 and suggest that co-targeting of PRDX6 or modulating miR-371-3p expression together with targeted cancer therapies may delay or prevent acquired drug resistance. PC9 stable cell lines expressing GFP vector or miR-371-3p were generated to study the effect of miR-371-3p in response to erlotinib treatment for RNA extraction and hybridization on Affymetrix microarrays. Stable cell lines were treated with DMSO or erlotinib for 24hrs and RNA isolated for analyzing the effect of miR-371-3p on gene expression upon erlotinib treatment.

2016-08-01 | E-GEOD-83120 | biostudies-arrayexpress

Transcriptome analysis by Illumina microarrays of the effect of overexpressing H2A.J mutants, or WT H2A.J or canonical H2A, on the transcriptome of WI-38hTERT fibroblasts

Project description:The intent of the experiment was to test the effect of overexpressing H2A.J-V11A, H2AJ-S123E, H2A.J-S123A, and H2A.J-CterH2A mutants, as well as WT-H2A.J and canonical H2A-type1, on the transcriptome of WI-38hTERT fibroblasts. pTRIPz based lentiviral constructs placing these coding sequences under tetON control were used to produce stable WI38hTERT cell lines for each construct. Expression of the constructs in proliferating cells was induced with 100 ng/ml doxycycline for è days. Transcriptomes were also compared with control proliferating WI-38hTERT and WI-38hTERT cells induced into senescence by incubation with 20 µM etoposide for 2 weeks followed by 1 week without etoposide.

2020-11-01 | E-MTAB-9706 | biostudies-arrayexpress

Gene expression profiling of MOLT4 human T-ALL cells in response to miR-22-3p overexpression

Project description:MicroRNAs can play important roles in gene regulation affecting both normal development and diseases, including cancer. This microarray experiment was performed to identify genes and pathways differentially expressed in MOLT4 T-leukemia cells engineered to overexpress hsa-pre-miR-22-3p. MOLT4 cells transduced with an empty or hsa-pre-miR-22-3p lentiviral vectors were collected, processed for RNA extraction and hybridized on Affymetrix Clariom™ S Human arrays (n=3 replicates/group). Raw microarray data are available together with the applied protocols.

2020-07-30 | E-MTAB-9280 | biostudies-arrayexpress

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signaling in human colorectal adenocarcinoma cells

Project description:Oxaliplatin (oxPt) resistance in colorectal cancers (CRC) is a major unsolved problem. Consequently, predictive markers and a better understanding of resistance mechanisms are urgently needed. To investigate if the recently identified predictive miR-625-3p is functionally involved in oxPt resistance, stable and inducible models of miR-625-3p dysregulation were analyzed. Ectopic expression of miR-625-3p in CRC cells led to increased resistance towards oxPt. The mitogen-activated protein kinase (MAPK) kinase 6 (MAP2K6/MKK6) – an activator of p38 MAPK - was identified as a functional target of miR-625-3p, and, in agreement, was down-regulated in patients not responding to oxPt therapy. The miR-625-3p resistance phenotype could be reversed by anti-miR-625-3p treatment and by ectopic expression of a miR-625-3p insensitive MAP2K6 variant. Transcriptome, proteome and phosphoproteome profiles revealed inactivation of MAP2K6-p38 signaling as a possible driving force behind oxPt resistance. We conclude that miR-625-3p induces oxPt resistance by abrogating MAP2K6-p38 regulated apoptosis and cell cycle control networks.

2017-03-29 | MSV000080762 | MassIVE

Hsa-miR-139-5p expression regulates the abundance of proteins related to poor survival cancer in CAL-62 thyroid cancer cell line

Project description:We studied the impact of hsa-miR-139-5p on the protein output by means of an iTRAQ-based approach. First, we established two CAL-62 isogenic cell lines expressing either the mature hsa-miR-139-5p or a non-targeting control upon a doxycycline inducible promoter (PTRE3G-tGFP, Dharmacon). Total proteins of P-tGFP-hsa-miR139-5p untreated or treated with doxycycline (1ug/ml) for 96 and 120 hours were isolated and labeled with iTRAQ® reagent 8-plex. Two independent experiments were performed.

2019-08-13 | PXD011901 | Pride

Analysis of DCIS using Clariom D transcriptomics array

Project description:Experiment description to give context to the data set: Ductal carcinoma in situ (DCIS), the most common type of pre-invasive lesion of breast, is being detected with increasing frequency with the advent of mammographic screening. Surgery is the mainstay for the treatment of DCIS. Based on the clinic-pathological features of DCIS, this may be followed by radiotherapy and/or endocrine therapy. The qualitative assessment of histological grade, expression of single protein biomarkers and more recently, mRNA analysis (DCIS Score) have been used to make these decisions. However, these factors do not fully predict the likelihood of development of invasive breast cancer treated with breast-conserving surgery. A majority of women with ductal carcinoma in situ (DCIS) receive breast-conserving surgery (BCS) but then face a risk of development of invasive breast cancer. Using Human Clariom D Pico Assay, we aim to compare the transcriptome profiles of DCIS in relation to development of invasive breast cancer (INV-BC) versus Non-INV-BC cases. Experimental Methods Clariom D Pico Human Transcriptome Array were performed according to Applied Biosystems/Thermo Fisher Scientific’s instructions. Experimental protocols are summarized in detail in Supplementary Methods (Supplementary Data). Sample annotation We compared the relative gene expression in development of invasive breast cancer (INV-BC) versus Non-INV-BC cases in Singapore cohort-59 cases (discovery cohort) and Italian cohort-50 cases (validation cohort). Microplate Plate and Well IDs are also provided as Clariom D ID list per cohort. Author information Dr. Sunil Badve is the Principal Investigator. Raw Data Probe Cell Intensity (CELL) and .ARR files which contain the design information for this study are provided (Human Clariom D Pico Assay).

2022-06-02 | E-MTAB-9856 | biostudies-arrayexpress

Expression data from differentiating ES cells expressing miR-200c and miR-141

2011-09-22 | GSE24289 | GEO

Exon Level Expression Profiling: a Novel Unbiased Transcriptome

Project description:Transcriptome analysis of partially fragmented RNA from EndoC BH1 human beta cells sorted by FACs Global gene expression profiling has shown great promise in identifying altered cell differentiation status from cultured cells. However, FACs sorting cells using internal markers causes the RNA to be partially fragmented. Clariom D pico arrays are able to utilise partially fragmented RNA to provide exon level definition to determine changes in both total gene expression and splicing.

2021-07-28 | GSE173423 | GEO

Expression data from differentiating ES cells expressing miR-200c and miR-141

Project description:ES cells express the miR-200 family which becomes down-regulated during the course of differentiation in serum. We generated an ES cell line which expresses miR-200c and miR-141 upon addition of doxycycline. Microarrays were used to gain a global picture of differentiation when miR-200c and miR-141 expression were maintained throughout differentiation through the addition of doxycycline. A2.miR200c ES cells, which express miR-200c/miR-141 upon addition of doxycycline, were differentiated as embryoid bodies in six petri dishes. Half of the samples were treated with doxycycline on days 2 and 4 of differentiation, and RNA was collected from all samples on days 3, 4, and 5.

2011-09-21 | E-GEOD-24289 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data